A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
← catalyst calendarNCT06890338 · readout ≤ 1,289 d
Sponsored by AbbVie (industry) · ABBV — their whole pipeline →. With GOG Foundation.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
140estimated
Sites
68
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-21 | actual | When the study began enrolling |
| Primary completion | Feb 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Feb 2030 | estimated | The whole study's end, after follow-up |
| First posted | 2025-03-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-14 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Epithelial Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Neoadjuvant
Interventions
- Drug: Carboplatin
- Drug: Mirvetuximab Soravtansine — also filed as MIRV, IMGN853, ELAHERE™
- Drug: Bevacizumab
Primary outcome
what the primary-completion date above is the date OFObjective Response (OR) by Independent Central Review (ICR)
measured Up to Approximately 3 years
Permalink · ABBV's whole pipeline · Catalyst calendar · Every registered study · What changed